Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Fineline Cube Dec 14, 2025
Company Deals

InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program

Fineline Cube Dec 14, 2025
Company Deals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Fineline Cube Dec 13, 2025
Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Fineline Cube Dec 13, 2025
Company Deals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

Fineline Cube Dec 13, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Fineline Cube Dec 14, 2025
Company Drug

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

Fineline Cube Dec 14, 2025
Company Deals

Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million

Fineline Cube Jul 16, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acquisition of a 95.09% stake in Shanghai-based...

Company Drug

Vigonvita’s Simenafil Receives NMPA Approval for Erectile Dysfunction Treatment

Fineline Cube Jul 16, 2025

Suzhou-based Vigonvita Life Sciences Co., Ltd., announced that it has received marketing approval from the...

Company Deals

Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development

Fineline Cube Jul 16, 2025

Shanghai-based Xgene Pharmaceutical Inc. has entered into a licensing agreement withNeuroGen Pharma, a neurology care...

Company Deals

Otsuka to Acquire Cantargia’s IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases

Fineline Cube Jul 16, 2025

Japan-based drug maker Otsuka (OTCMKTS: OTSKY) is set to acquire from Swedish biotech Cantargia AB...

Company Drug

Huadong Medicine Receives FDA Approval for Clinical Trials of Innovative ADC HDM2020

Fineline Cube Jul 15, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...

Company Deals

Ningbo Health Gene and Biofast Biotech Partner to Advance Genetic Testing for Hereditary Diseases

Fineline Cube Jul 15, 2025

Chinese firms Ningbo Health Gene Technologies Co., Ltd. and Biofast Biotechnology Co., Ltd. announced late...

Company Deals

Boehringer Ingelheim Licenses Spevigo to LEO Pharma for Global Dermatology Expansion

Fineline Cube Jul 15, 2025

German pharmaceutical giant Boehringer Ingelheim (BI) this week announced a licensing agreement with Denmark-based dermatology...

Company Medical Device

Peijia Medical Completes First Patient Implantation for MonarQ TTVR System in Global Clinical Study

Fineline Cube Jul 15, 2025

China-based Peijia Medical Ltd (HKG: 9996) announced the successful completion of the first patient implantation...

Company Deals

Golden Age Health Secures Exclusive Rights to Innostellar’s Gene Therapy LX-101 in China

Fineline Cube Jul 15, 2025

Singapore-based Golden Age Health, a specialty pharmaceutical company focused on rare and specialty diseases, has...

Company Drug

Merck Initiates EXPrESSIVE Phase III Trial for Once-Monthly HIV PrEP Drug MK-8527

Fineline Cube Jul 15, 2025

Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) announced the initiation of the EXPrESSIVE Phase...

Company Drug

China Medical System’s CMS-D001 Gains NMPA Approval for Atopic Dermatitis Trials

Fineline Cube Jul 15, 2025

China Medical System Holdings Limited (CMS; HKG: 0867) announced that it has received clinical trial...

Policy / Regulatory

NHSA Reports 2024 Healthcare Stats: BMI Fund Reaches RMB 3.49 Trillion Income with 95% Participation Rate

Fineline Cube Jul 15, 2025

The National Healthcare Security Administration (NHSA) this week released its national medical and healthcare development...

Company Drug

SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data

Fineline Cube Jul 15, 2025

SinoMab BioScience Ltd (HKG: 3681) announced the voluntary withdrawal of its Biologics License Application (BLA)...

Company Deals

Mabwell Signs Licensing Agreement with Unilab for Denosumab Biosimilars in the Philippines

Fineline Cube Jul 15, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced a licensing agreement with Unilab, Inc.,...

Company Deals

Innovent Biologics and JD Health Form Strategic Partnership to Enhance Drug Supply and Healthcare Services

Fineline Cube Jul 15, 2025

China-based Innovent Biologics Inc., (HKG: 1801) and JD Health International Inc., (HKG: 6618) have officially...

Company Drug

Shanghai Henlius Biotech Initiates US Patient Dosing in Phase III Trial for HER2-Positive Gastric Cancer

Fineline Cube Jul 15, 2025

China-based Shanghai Henlius Biotech Inc., (HKG: 2696) announced the first patient dosing in the US...

Company Drug

Bayer AG’s Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction ≥40%

Fineline Cube Jul 15, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from...

Company Drug

Sichuan Biokin’s Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma

Fineline Cube Jul 15, 2025

China’s Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...

Company Deals

Hunan Mabgeek Biotech Files for Hong Kong IPO to Expand Innovative Biologics Pipeline

Fineline Cube Jul 15, 2025

China-based Hunan Mabgeek Biotech Co., Ltd has submitted an application to the Hong Kong Stock...

Company Drug

GSK’s Arexvy RSV Vaccine Expansion for Adults 18-49 Receives FDA Review

Fineline Cube Jul 15, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has...

Posts pagination

1 … 58 59 60 … 597

Recent updates

  • Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation
  • Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal
  • Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial
  • Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment
  • InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation

Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Company Drug

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Company Drug

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.